Information Provided By: 
Fly News Breaks for June 19, 2017
CLVS, TSRO
Jun 19, 2017 | 08:27 EDT
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.
News For TSRO;CLVS From the Last 2 Days
There are no results for your query TSRO;CLVS
